maridebart cafraglutide vs tirzepatide — a GLP-1 receptor agonist and glucose-dependent insulinotropic polypeptide receptor antagonist — is being studied as a once-monthly obesity treatment. Research findings from the MariTide phase 2 trial are summarized maridebart cafraglutide vs tirzepatide Once-Monthly
Pay in 4 interest-free payments of $5.11 Learn more
Shipping Estimate
USA
- USA
- CAN
- USA
- CAN
Ships within 48 hours · Estimated delivery Sep 2 - Sep 7





























